麻豆社国产

Skip to content

J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders

Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies.
972cfe39171007c8d6375ba177ab1e0a8d8365fd2b3b0e4a74f042171c145053
FILE - The Johnson & Johnson headquarters in New Brunswick, New Jersey, on Feb. 8, 2024. (AP Photo/Ted Shaffrey, File)

Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies.

The health care giant said Monday that it will pay $132 in cash for each share of Intra-Cellular. That represents a 39% premium to Intra-Cellular鈥檚 closing price of $94.87 on Friday.

Shares of both companies climbed Monday after announcing the deal.

Intra-Cellular Therapies Inc. makes Caplyta, a once-daily pill for treating adults with schizophrenia and depression tied to bipolar disorder. The drug brought in $175 million in last year鈥檚 third quarter as total prescriptions increased 38%.

Intra-Cellular said last fall it was expanding its sales force to target growth opportunities with primary care doctors. The company also is seeking U.S. Food and Drug Administration approval to use the drug as supplemental treatment for adults with major depressive disorder.

Wall Street expects sales of the drug to grow past $1 billion next year and top $2.5 billion by 2028, according to the data firm FactSet.

Intra-Cellular鈥檚 pipeline of drugs under development also includes a potential treatment for anxiety and psychosis and agitation tied to Alzheimer鈥檚 disease. That drug is in mid-stage testing.

J&J, based in New Brunswick, New Jersey, says it will pay for the deal, valued at about $14.6 billion, with a combination of cash and debt. The companies expect the deal to close later this year.

Monday鈥檚 announcement comes a few days after Intra-Cellular settled a patent lawsuit over when a cheaper, generic version of Caplyta can enter the U.S. market. The company said Friday that drugmaker Sandoz Inc. can start selling a generic version in 2040 or earlier under circumstances it didn鈥檛 detail in a brief statement.

The company has submitted the deal to federal regulators for review, and it still has other patent cases pending in federal court.

Shares of Intra-Cellular, based in Bedminster, New-Jersey, jumped about 34% to $127.10 Monday. J&J鈥檚 stock edged up 1% to $143.45

Tom Murphy, The Associated Press

push icon
Be the first to read breaking stories. Enable push notifications on your device. Disable anytime.
No thanks